Clinical trials
Completed Phase 2 Recurrence trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
393 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 7 |
| 2001 | 9 |
| 2002 | 9 |
| 2003 | 9 |
| 2004 | 19 |
| 2005 | 18 |
| 2006 | 20 |
| 2007 | 20 |
| 2008 | 11 |
| 2009 | 26 |
| 2010 | 17 |
| 2011 | 22 |
| 2012 | 24 |
| 2013 | 22 |
| 2014 | 19 |
| 2015 | 19 |
| 2016 | 10 |
| 2017 | 16 |
| 2018 | 19 |
| 2019 | 12 |
| 2020 | 13 |
| 2021 | 16 |
| 2022 | 6 |
| 2023 | 1 |
| 2024 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 393 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Fred Hutchinson Cancer Center | 19 |
| Novartis Pharmaceuticals | 15 |
| Celgene | 10 |
| Memorial Sloan Kettering Cancer Center | 9 |
| GlaxoSmithKline | 7 |
| M.D. Anderson Cancer Center | 7 |
| Amgen | 6 |
| AstraZeneca | 6 |
| Merck Sharp & Dohme LLC | 5 |
| National Cancer Institute (NCI) | 5 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Recurrence | 393 |
| Multiple Myeloma | 73 |
| Lymphoma | 58 |
| Lymphoma, Large B-Cell, Diffuse | 55 |
| Lymphoma, Non-Hodgkin | 55 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 53 |
| Hodgkin Disease | 52 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 52 |
| Leukemia, Myeloid, Acute | 48 |
| Burkitt Lymphoma | 44 |
Trials
Showing 1 to 25 of 393. Each trial links to its page on Pharma Observatory.
293 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.